Blade is actively seeking to in-license clinical or pre-clinical assets to expand our pipeline of products to treat fibrosis. We are seeking to evaluate opportunities that represent a wide variety of molecular targets.
Parties developing products or technologies for fibrotic diseases that are interested in collaborating with Blade should contact our business development team. Contact: email@example.com
Blade has partnered with the Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Our founder, Hal Dietz, M.D., has been working closely with SRF for several years, and Blade has provided support through its research grant program.